Ischemic stroke is one of the major diseases of causing adult disability and death.Age,sex,smoking,hypertension,and diabetes,etc.are the risk factors for ischemic stroke,but they can only partially explain the reasons of stroke onset.Twins,families,and single-gene genetic stroke studies have shown that ischemic stroke has obvious genetic predisposition.In recent years,genomics has made remarkable progress in ischemic stroke study and has shown that many new single nucleotide polymorphisms or genes are associated with ischemic stroke and its risk factors.However,the contribution of these genetic genes for ischemic stroke is still too small and the repetitive studies are needed for further confirmation.

Currently targeted therapy of breast cancer therapy has become the hot research field and a kind of brand-new biological treatment mode after three traditional pattern of the surgery, radiotherapy and chemotherapy for breast cancer. Molecular targeted therapy is aimed at the target that may cause cancer cells, such as protocarcinogenic genes and tumor-suppressor genes, cell signaling pathways, cytokines and receptors, antiangiogenesis etc. It can reverse malignant biology behavior to inhibit tumor cell growth from the molecular level and has the advantages of high specific effects and low side effects. This paper focuses on the drug of the molecular targeted therapy for breast cancer and the latest progress of targeted therapy.

Objective To establish the quality standard for Kangyuan Granula. Methods Radix Astragali, Radix Paeoniae Alba, Fructus Lycii and Radix et Rhizoma Glycyrrhizae in this prescription were identified by TLC. The content of the Paeoniflorin was determined by HPLC. The column of AichromBond-AQ-C18 (4.6 mm?150 mm, 5 ?m) was used, the mobile phase was Water-Acetonitrile (85∶15), at the flow of 1.0 mL/min, the column temperature of 30 ℃, and peaks were detected at 230 nm. Results The characteristic of identification by TLC was distinct and highly specific. The linear range of Paeoniflorin was 0.0545～0.545 ?g, r =0.999 5, the average recovery was 97.90%, RSD=1.06% (n =6). Conclusion The method was easy to operate with accurate result and good reproducibility. It can be used effectively for the quality control of this preparation.

OBJECTIVE: To establish a bacterial endotoxin test method for fluorescein sodium injection.METHODS: Based on the bacterial endotoxin test method stated in Chinese Pharmacopoeia 2005 edition(second part),an interference test was conduced on different batches of fluorescein sodium samples using tachypleus amebocyte lysate from different companies.RESULTS: At a concentration of no more than 0.75 mg?mL-1,fluorescein sodium showed no interfere with the bacterial endotoxin test.CONCLUSION: It is feasible for bacterial endotoxin test of fluorescein sodium injection be conducted in a limit value of 0.15 EU?mL-1.

Acupuncture Points ; Acupuncture Therapy ; Humans ; Male ; Middle Aged ; Multiple System Atrophy ; therapy ; Treatment Outcome

Antioxidants ; metabolism ; therapeutic use ; Bronchopulmonary Dysplasia ; drug therapy ; etiology ; metabolism ; Humans ; Hyperoxia ; complications ; Infant, Newborn ; Lung ; metabolism ; Reactive Oxygen Species ; metabolism

Acupuncture Points ; Acupuncture Therapy ; Adolescent ; Guillain-Barre Syndrome ; therapy ; Humans ; Male

Urine albumin measurements are widely used to identify and monitor patients with kidney damage. The time of sample collection and the cut-off point which are used for interpretation are the important issues for the use of urine albumin measurements have been discussed. More clinical researches and investigations are needed in order to acquire the support from evidence-based medicine.

Recently, several large, long-term rendomized controlled trails (ACCORD, ADVANCE, VADT) and long-term epidemiologic follow-up studies (UKPDS, STENO-2) have compared the effects of intensive versus standard glycemic control on cardiovascular disease events. Based on reviewing aforementioned studies, the present article would suggest that intensive glycemia control is still considered as one of the principal therapies for the prevention of cardiovascular events in diabetes while stressing on safety and individualization for glucose-lowering strategy.

Point-of-care testing systems has been rapidly and widespreadly used in clinical practice.We ought to think about the speed, cost, quality and other aspects of the testing and formulate clinical guidelines for POCT as soon as possible.That will help to assure the reliable results of POCT and the correct application in the clinical management.